Cutler Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cutler Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,900	Closed	-$2K	–	5311
2021 Q4	$2K	Sell	2,900 -22,500	-89%	-$298K	﹤0.01%	4664
2021 Q3	$47K	Buy	25,400 +14,500	+133%	+$229K	﹤0.01%	2547
2021 Q2	$24K	Buy	+10,900	New	+$148K	﹤0.01%	3127
2019 Q1	–	Sell	-11,000	Closed	-$6K	–	4031
2018 Q4	$6K	Buy	11,000 +3,100	+39%	+$24.1K	﹤0.01%	2803
2018 Q3	$5K	Buy	+7,900	New	+$53.1K	﹤0.01%	3013
2017 Q4	–	Sell	-7,000	Closed	-$2K	–	4899
2017 Q3	$2K	Sell	7,000 -1,400	-17%	-$7.17K	﹤0.01%	5012
2017 Q2	$13K	Buy	+8,400	New	+$51.2K	﹤0.01%	3866
2017 Q1	–	Sell	-8,500	Closed	-$7K	–	6359
2016 Q4	$7K	Buy	+8,500	New	+$44.2K	﹤0.01%	4561
2016 Q1	–	Sell	-5,700	Closed	-$16K	–	6474
2015 Q4	$16K	Buy	+5,700	New	+$56.7K	﹤0.01%	3621

Other funds holding BCRX

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Cutler Group's BCRX Position: Q3 2022 in Review

Cutler Group sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2022, closing a stake of 1,443 shares — an estimated $18.6K sold.

Cutler Group first reported a position in BCRX in Q4 2015 and held it in 20 quarters. The position peaked at $331K in Q3 2021. 234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

Cutler Group reported no remaining BioCryst Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Cutler Group sold 1,443 BioCryst Pharmaceuticals shares in Q3 2022, an estimated $18.6K.
Cutler Group first reported a position in BioCryst Pharmaceuticals in Q4 2015 and held it in 20 quarters.
Cutler Group's BioCryst Pharmaceuticals position peaked at $331K in Q3 2021.
234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.